Low levels of the enzyme ADAMTS13 and elevated inflammatory markers such as interleukin-6 (IL-6) are associated with worse outcomes in patients with acute myeloid leukaemia (AML). The gene discussed is ADAMTS13; the disease is acute myeloid leukemia.